Videos
Long-Term Goals of Guidelines for Painful Diabetic Neuropathy: Brian Callaghan, MD, MS
October 14th 2022The associate professor at the University of Michigan described the ways recently published guidelines on diabetic neuropathies will change how conditions like Guillain-Barré syndrome and CIDP are managed. [WATCH TIME: 3 minutes]
AMX0035’s Safety as a Treatment for Patients with ALS: Lawrence Steinman, MD
October 12th 2022The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses the biggest takeaway from the FDA approval of Amylyx’s therapy, marketed as Relyvrio, and the availability of the treatment for patients with ALS. [WATCH TIME: 5 minutes]
Approval of AMX0035 and the Future of Clinical Trials for ALS: Lawrence Steinman, MD
October 11th 2022The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discussed updates in ALS research along with the need in future studies following AMX005’s (Relyvrio; Amylyx Pharmaceuticals) recent FDA approval. [WATCH TIME: 4 minutes]
Understanding the Complexity and Heterogenicity of Alzheimer Disease: Thomas Wisniewski, MD
October 11th 2022The director of NYU Langone’s Alzheimer’s Disease Research Center and Center for Cognitive Neurology discussed current knowns and unknowns about the pathology of Alzheimer disease. [WATCH TIME: 4 minutes]
Approach to Poststroke Neuromuscular and Motor Symptoms: Wayne Feng, MD, FAHA
October 10th 2022The division chief of stroke and vascular neurology at Duke Health provided insight on the nuances of poststroke neuromuscular symptoms and how they differ from other typically managed impairments. [WATCH TIME: 5 minutes]
Breakthrough in ALS With FDA Approval of AMX0035: Lawrence Steinman, MD
October 10th 2022The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses Amylyx’s therapy that was recently approved by the FDA, and what it means for the ALS community and the global healthcare industry. [WATCH TIME: 5 minutes]
Unique Aspects of Caring for Women With Multiple Sclerosis: Riley Bove, MD
October 7th 2022The neurologist at the University of California, San Francisco offered an overview of the State of the Science Summit that was held on September 28, 2022, featuring a panel of expert clinicians. [WATCH TIME: 7 minutes]
AUPN 2022 Veterans Health Administration Workshop
Glenn Graham, MD, PhD; and Sharyl Martini, MD, PhD, moderate a discussion with 4 clincial experts to advance specialized clinical care, education and research for Veterans with movement disorders, multiple sclerosis, epilepsy and seizures, and headache. [WATCH TIME: 1 hour, 52 minutes]
Institutional Perspectives in Neurology, Chaired by Riley Bove, MD
October 5th 2022Chaired by Riley Bove, MD, of the University of California, San Francisco (UCSF), the presentations also feature Emmanuelle Waubant, MD, PhD, of UCSF; William L. Conte, MD, MS, of Methodist Hospitals; and Maria K. Houtchens, MD, of Harvard Medical School. [WATCH TIME: 1 hour, 31 minutes]
Limits, Cautions When Using NuroSleeve to Restore Arm Function: Joe Kardine, MS, OTR, CBIS
October 4th 2022The clinical program manager at the Jefferson Center for Neurorestoration discussed certain scenarios in which the NuroSleeve system may not be applicable for patients with neurological disorders. [WATCH TIME: 3 minutes]
Progression of New Treatments for Duchenne Muscular Dystrophy: Emma Ciafaloni, MD
October 3rd 2022The professor of Neurology and Pediatrics at University of Rochester Medical Center discusses the progression of new treatment for Duchenne muscular dystrophy and provides suggestions for moving forward with research in the field. [WATCH TIME: 5 minutes]
Recommendations for Clinical Trial Design in Duchenne Muscular Dystrophy: Emma Ciafaloni, MD
October 2nd 2022The professor of neurology and pediatrics at University of Rochester Medical Center gives some recommendations for the improvement in clinical trial design for patients with rare diseases such as Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]
Understanding Safety, Amyloid-Related Imaging Abnormalities With Lecanemab: Sharon Cohen, MD, FRCPC
September 30th 2022The neurologist and assistant professor at the University of Toronto discussed the real, but tepid significance of amyloid-related imaging abnormalities seen from lecanemab in early-stage Alzheimer disease. [WATCH TIME: 3 minutes]
Assessing Lecanemab’s Effect in Early Alzheimer Disease: Sharon Cohen, MD, FRCPC
September 28th 2022The neurologist and assistant professor at the University of Toronto provided insight on positive topline findings from the phase 3 Clarity AD study of lecanemab in early Alzheimer disease. [WATCH TIME: 4 minutes]
New Treatments for Duchenne Muscular Dystrophy: Emma Ciafaloni, MD
September 27th 2022New Treatments for Duchenne Muscular Dystrophy: Emma Ciafaloni, MD The professor of Neurology and Pediatrics at University of Rochester Medical Center discusses the new and future treatments for Duchenne muscular dystrophy. [WATCH TIME: 4 minutes]
